(Q37588720)

21 August 2017

1 reference

title

Targeting IL-6 in the treatment of inflammatory and autoimmune diseases (English)

1 reference

21 August 2017

0 references

2

Flavia Cicuttini

1 reference

21 August 2017

4

Graeme Jones

1 reference

21 August 2017

1

Changhai Ding

1 reference

21 August 2017

Jun Li

3

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 October 2009

1 reference

Expert Opinion on Investigational Drugs

21 August 2017

published in

1 reference

21 August 2017

volume

18

1 reference

21 August 2017

issue

10

1 reference

21 August 2017

page(s)

1457-1466

1 reference

Anti-interleukin-6 receptor antibody treatment in inflammatory autoimmune diseases

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203789

Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203789

Interleukin-6: discovery of a pleiotropic cytokine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203789

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203789

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203789

Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203789

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203789

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203789

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203789

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203789

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203789

Successful treatment of resistant pseudogout with anakinra

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203789

Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203789

A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203789

Women in academic rheumatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203789

Exacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving humanised anti-interleukin-6 receptor monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203789

Interleukin-6-deficient mice develop mature-onset obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203789

10.1517/13543780903203789

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference